Search

A recent report from Massachusetts General Hospital discusses the development and validation of time-to-event models to predict metastatic recurrence of localized cutaneous melanoma. The study aimed to identify patients at high risk of metastatic recurrence who would benefit from immunotherapy. The researchers used machine learning models and extracted data from electronic health records to evaluate the performance of the models. The results suggest that these models can reliably predict metastatic recurrence and help identify high-risk patients for immunotherapy. However, it is important to note that the study was retrospective and based on a cohort from one geographic area. [Extracted from the article]